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Abstract
Progenitors of the first hematopoietic cells in the mouse arise in
the early embryo from Brachyury-positive multipotent cells in the
posterior-proximal region of the epiblast, but the mechanisms that
specify primitive blood cells are still largely unknown. Pluripotency
factors maintain uncommitted cells of the blastocyst and embry-
onic stem cells in the pluripotent state. However, little is known
about the role played by these factors during later development,
despite being expressed in the postimplantation epiblast. Using a
dual transgene system for controlled expression at postimplanta-
tion stages, we found that Nanog blocks primitive hematopoiesis
in the gastrulating embryo, resulting in a loss of red blood cells
and downregulation of erythropoietic genes. Accordingly, Nanog-
deficient embryonic stem cells are prone to erythropoietic dif-
ferentiation. Moreover, Nanog expression in adults prevents the
maturation of erythroid cells. By analysis of previous data for
NANOG binding during stem cell differentiation and CRISPR/Cas9
genome editing, we found that Tal1 is a direct NANOG target. Our
results show that Nanog regulates primitive hematopoiesis by
directly repressing critical erythroid lineage specifiers.
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Introduction
Blood cells first appear during mouse development in the extraem-
bryonic yolk sac at embryonic day (E) 7.5. These are primarily
erythroid cells, needed to provide oxygen for the exponential
embryo growth at these stages (Baron et al, 2012). This initial prim-
itive hematopoiesis is not generated by hematopoietic stem cells,
which first appear later in development (around E10.5) and provide
the basis for definitive hematopoiesis (Jagannathan-Bogdan & Zon,
2013).
The precursors of the first erythroid cells are already present at
the initial stages of gastrulation, in the nascent mesoderm at the
posterior end of the embryo (Lawson et al, 1991; Huber et al,
2004); moreover, detailed fate mapping suggests that these cells are
specified in the epiblast before gastrulation (Kinder et al, 1999;
Padron-Barthe et al, 2014). Hematopoietic precursors are specified
after the determination of the early mesoderm from the epiblast,
which is driven by the sequential action of the transcription factors
encoded by Brachyury and Mesp1 and ends in the expression of
FLK1 (encoded by Kdr), which marks most mesodermal cells at
gastrulation (Pfister et al, 2007; Chan et al, 2013; Scialdone et al,
2016). Subsequently, primitive hematopoiesis progenitors start
expressing a battery of lineage-specific transcription factor genes
such as Tal1, Gata1, and Klf1 as they migrate to the extraembryonic
region and generate the blood islands of the yolk sac (Dore &
Crispino, 2011; Baron et al, 2012).
Despite the knowledge acquired in recent years on the regulation
of gastrulation and lineage determination of blood cells, we still do
not fully understand how hematopoietic precursors are specified
from within the pool of common mesodermal cells present in the
posterior-proximal region of the gastrulating embryo. In other
words, it remains unclear how the first differentiated cell type to
appear in the postimplantation embryo (the primitive hematopoietic
cells) is specified from a multipotent population of mesodermal
progenitors, and how lineage-specific genes are turned on in this
rapid transition. In this study, we provide evidence for an involve-
ment in this process of the homeobox transcription factor gene
Nanog.
NANOG is a constituent of the core set of transcription factors,
together with OCT4 and SOX2, involved in establishing and main-
taining embryonic pluripotency, both in the blastocyst and in
embryonic stem (ES) cells in culture (Chambers & Tomlinson,
2009). Loss of Nanog in the early blastocyst results in embryonic
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death at implantation (Mitsui et al, 2003); however, Nanog-deficient
ES cells are still able to maintain pluripotency, although they are
prone to differentiate (Chambers et al, 2007). In the preimplantation
embryo, Nanog is expressed throughout the epiblast. During implan-
tation, Nanog is turned off, only to be re-expressed at E6.0 in the
posterior part of the epiblast, where the primitive streak will form
and gastrulation takes place shortly after (Hart et al, 2004; Osorno
et al, 2012). Later, expression is restricted to primordial germ cells,
with Nanog playing a crucial role in their development (Chambers
et al, 2007; Yamaguchi et al, 2009; Zhang et al, 2018). Aside from
its function in the germline, there is little or no previous evidence
for Nanog playing any other role in the postimplantation epiblast or
in the gastrulating embryo.
Here, we show that sustained expression of Nanog beyond gastru-
lation blocks differentiation of red blood cells during primitive hema-
topoiesis. This phenotype can be recapitulated in the adult, where
Nanog leads to an increase in the number of megakaryocyte–
erythroid precursors (MEPs), possibly by blocking their differentia-
tion. Hematopoietic differentiation of Nanog-deficient ES cells is
enhanced, further supporting the hypothesis that Nanog blocks the
erythroid lineage in the epiblast of the gastrulating embryo. Further-
more, by re-analyzing single-cell RNA-seq data from gastrulating
embryos (Scialdone et al, 2016) and NANOG ChIP-seq data in ES and
epiblast-like cells (Murakami et al, 2016), together with CRISPR/
Cas9-mediated genome editing, we found that NANOG directly
represses the expression of the erythroid specifier Tal1. Together,
these findings suggest that Nanog controls the early specification of
hematopoietic cells from mesodermal precursors during gastrulation.
Results
Nanog blocks erythropoiesis in developing mouse embryos
Nanog loss of function is lethal at preimplantation stages (Mitsui
et al, 2003), therefore preventing analysis of the putative role of
Nanog later in development, when it is re-expressed at the posterior
part of the gastrulating embryo (Hart et al, 2004). To overcome this
obstacle, we used an inducible TetON transgenic model (Nanogtg) in
which Nanog expression is induced by the administration of doxycy-
cline (dox) (Piazzolla et al, 2014). We induced Nanog from E6.5 in
order to prolong its expression beyond E7.5, when it is normally
turned off (Hart et al, 2004), and examined the embryos at E9.5.
Visual examination of freshly dissected dox-treated embryos showed
some growth retardation and craniofacial defects, but the most
notable effect was a lack of blood (Fig 1A). To confirm this observa-
tion, we carried out whole-mount in situ hybridization for Hbb-bh1,
which encodes the beta-like embryonic hemoglobin (Wilkinson
et al, 1987) and for Redrum, an erythroid-specific long non-coding
RNA (Alvarez-Dominguez et al, 2014; Paralkar et al, 2014). In
untreated (control) Nanogtg embryos at E9.5, Hbb-bh1 labels primi-
tive red blood cells that are distributed throughout the yolk sac.
Expression of Nanog up to this stage resulted in near complete
blockade of Hbb-bh1 expression (Fig 1A). Redrum is expressed in
the developing aorta-gonad-mesonephros (AGM) region, surely
from erythroid cells circulating along the aorta, and in the tail bud.
Nanog induction led to loss of Redrum expression in the AGM
region, but interestingly not in the tail bud that is not a site of
embryonic erythropoiesis (Fig 1A). We also checked if the apparent
lack of blood was accompanied by vascular defects. Immunostain-
ing for Endomucin, expressed in embryonic endothelial cells,
revealed no substantial differences at E9.5 between dox-treated and
untreated Nanogtg embryos, as is observed in the correct patterning
of intersomitic vessels (Fig 1B). Furthermore, CD31 staining showed
that yolk sac vasculature was equally unaffected in dox-treated
embryos (Fig EV1A). We also examined heart morphology at these
stages, to address if other mesodermal derivatives showed develop-
mental defects. Hearts of freshly dissected E9.5 dox-treated embryos
beat normally, and both overall morphology and histological
sections showed no defects (Fig EV1B). Prolonged Nanog expres-
sion in the embryo thus causes a deficit in primitive red blood cells
that is accompanied by lack of expression of erythroid-specific
genes, but does not affect early vascular or cardiac development.
To characterize the effect of Nanog induction on hematopoiesis,
we analyzed progenitors and red blood cells by flow cytometry of
dispersed individual yolk sacs from E9.5 embryos using c-Kit (a
marker of early uncommitted progenitors), CD41 (erythroid progeni-
tors; Mitjavila-Garcia et al, 2002), CD71, and Ter119 (Borges et al,
2012). Dox-treated Nanogtg embryos showed a dramatic reduction in
erythroblast cells (CD71+ Ter119+; Fig 1C and D), which supports
the above results. However, the total number of hematopoietic
progenitor populations (cKit+CD41+ and CD41+, respectively)
remained unchanged (Fig 1E and F). We examined the morphology
of erythroblasts from circulating blood of E9.5 dox-treated and
untreated embryos by Giemsa staining (Fraser et al, 2007) and found
that the few remaining primitive erythroid cells showed a normal
morphology (Fig EV1C). Taken together, these results suggest that
Nanog causes a blockade in hematopoietic progenitors, preventing
their differentiation toward erythroblast cells.
Nanog downregulates the expression of key erythroid
determination genes
We next investigated how prolonged Nanog expression to E9.5 influ-
ences hematopoietic gene expression. For this, we isolated progeni-
tor and mature populations by flow cytometry as described above
(Fig 1C and D), and conducted RT–qPCR to examine the expression
of core lineage determinants of hematopoietic fate: Tal1, Runx1,
Gata1, and Klf1 (Palis et al, 1999; Yokomizo et al, 2008; Kuvardina
et al, 2015). Gain of Nanog expression in erythroblasts (CD71+
Ter119+ population) resulted in significant downregulation of Tal1
and increase of Runx1 (Fig 1G). However, despite consistent gain of
Nanog expression, we did not observe differences of gene expres-
sion in earlier progenitors (Fig EV1D).
To examine whether similar changes occur at earlier stages, we
induced Nanog expression from E5.5 to E7.5, a time window span-
ning initiation of primitive hematopoiesis. Whole-mount in situ
hybridization showed decreased expression of Gata1 and Klf1 in the
extraembryonic region, corresponding to the blood island domain
(Fig EV1E). RT–qPCR of individual dox-treated or control E7.5
Nanogtg embryos showed decreased expression of the core erythro-
poietic genes Tal1, Gata1, and Klf1 but no change in Runx1
(Fig EV1F). A possible explanation for our observations would be
that Nanog expression causes a general blockade of mesodermal
specification, with the downregulation of early hematopoiesis genes
being merely a secondary effect of this. We therefore tested the
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expression of lineage determinants expressed at gastrulation
(Brachyury and Eomes) and the early mesodermal gene Kdr (Shalaby
et al, 1995; Palis et al, 1999). Exogenous Nanog induced the expres-
sion of both Brachyury and Eomes, in line with published data (Teo
et al, 2011), but did not alter Kdr expression (Fig EV1F). Together,
these results suggest that Nanog blocks erythroid fate and is able to
specifically downregulate the early expression of erythropoietic
genes during the initial determination of primitive hematopoiesis.
Nanog-induced hematopoietic defects are cell intrinsic
The results presented so far suggest that Nanog blocks specifically
erythroid progenitors during primitive hematopoiesis. To test if this is
the case, we aimed to rescue the observed genotype by generating
chimeric embryos by injection of wild-type ES cells constitutively
expressing GFP (Diaz-Diaz et al, 2017) into Nanogtg blastocysts. The
resulting embryos were treated in uterowith dox at E6.5 and examined
for GFP fluorescence at E10.5. Those showing no overall contribution
(no GFP+ cells) were used as controls, whereas embryos containing
GFP+ cells were considered chimeras (Fig 2A and B). Erythroid cells
were evaluated in individual embryos by flow cytometry analysis of
CD71 and Ter119, as described earlier (Fig 1E and F).
Chimeras with high contribution of wild-type ES cells had circu-
lating blood in both the embryo and the yolk sac, despite dox treat-
ment, contrasting with embryos with no contribution (Fig 2B).
Chimeras showed a recovery of erythroid cells, with high contribu-
tion from GFP+ wild-type ES-derived cells (Fig 2C). Quantification
of erythroid populations in chimeras showed an increased content
of CD71+ Ter119+ cells (Fig 2D); this increase did not occur when
the experiment was repeated without dox treatment (Fig 2E). The
number of GFP cells (derived from Nanog expressing cells) in dox-
treated chimeras did not differ from that in controls (with no contri-
bution of GFP+ cells), demonstrating that the recovery of the
erythroid populations in chimeras was entirely due to the wild-type
ES cells (Fig 2F). These results indicate that the effect of Nanog on
erythroid progenitors is primarily cell autonomous, and not
secondary to Nanog-induced changes in other cell types.
Loss of Nanog enhances hematopoietic differentiation of ES cells
To investigate the effect of the absence of Nanog on the erythroid
lineage, we tested the potential of ES cells with homozygous Nanog
loss of function (Chambers et al, 2007) to differentiate into blood
cells in culture (Irion et al, 2010). Nanog/ and wild-type control
ES cells of the parental strain (E14Tg2a) were used to generate
embryoid bodies (EB). EBs were allowed to differentiate for up to 7
days in hematopoietic differentiation media. After disaggregation
and culture, different colony-forming units (CFU) were scored
between days 5 and 7 (D5–D7; Fig 3A). Despite a trend for a
decrease in the number of common myeloid progenitors (CFU-
GEMM), Nanog/ EBs generated significantly more primitive
erythroid colonies (Ery-P) than controls, as well as a significantly
higher number of mature erythroid colonies (BFU-E; burst forming
unit erythroid) in the presence of cytokines driving a broader
hematopoietic differentiation. Interestingly, there was no between-
genotype difference in granulocyte–monocyte (CFU-GM) progeni-
tors, but monocyte (CFU-M) or granulocyte (CFU-G) progeni-
tors were produced more abundantly from wild type than from
Nanog/ EBs (Fig 3A). This last observation is possibly due to a
decrease in common myeloid progenitors together with a significant
increase of erythroid progenitors in the mutants. Nanog/ ES cells
thus have an increased potential for specific differentiation to red
blood cells.
To investigate how the absence of Nanog affects the gene
networks involved in erythroid specification, we monitored control
and Nanog/ ES-derived EBs for the expression of selected markers
over 10 days of differentiation. Brachyury expression was examined
as a marker of initial mesoderm specification, a necessary first step
for the establishment of hematopoietic lineages in EBs (Fehling
et al, 2003). Brachyury expression markedly increased at day 3 in
wild-type cells, as previously described (Robertson et al, 2000), but
in Nanog/ EBs this expression peak was delayed until day 5
(Fig 3B). Nanog is thus likely required for the correct temporal acti-
vation of Brachyury. We next checked the expression of genes
encoding the erythroid-specific factors Tal1, Gata1, and Klf1 and the
embryonic hemoglobin gene Hbb-bh1. In wild-type EBs, erythroid
gene expression peaks around day 5, 2 days after Brachyury activa-
tion. In Nanog/ EBs, erythroid gene expression peaked a day
later, at day 6. However, this is only 1 day after the onset of
Brachyury expression, contrasting the 2-day delay in wild-type EBs
(Fig 3B). Given the requirement of Brachyury expression for
hematopoietic differentiation (Fehling et al, 2003), we aligned the
expression dynamics of wild-type and Nanog/ cells to the day of
Brachyury induction (Fig EV2A). To validate this approach, we
▸Figure 1. Effect of Nanog on erythropoietic development.A Dox-induced prolongation of Nanog expression in Nanogtg embryos up to E9.5 results in lack of blood (left) and downregulation of erythropoietic gene expression. The
center and right panels show whole-mount in situ hybridization for Hbb-bh1 (in embryos with intact yolk sacs) and for the long non-coding RNA Redrum. Asterisks
mark the aorta-gonad-mesonephros (AGM) region and arrows the tail bud. Embryos of the same genotype but not treated with dox were used as controls (dox).
Scale bars, 500 lm.
B Endomucin staining of vessels in control (dox) or treated (+dox) E9.5 Nanogtg embryos. On the right, higher magnifications of the boxed areas. Scale bar, 500 lm.
C Representative FACS plot of the distribution of the CD71 and Ter119 populations in dissected yolk sacs from untreated and dox-treated E9.5 Nanogtg embryos.
D Quantification of the CD71+ Ter119+ population in controls (dox, black dots; n = 8) and Nanog expressing (+dox, red dots; n = 7) E9.5 yolk sacs. Each replicate
contained a pool of 5 (dox) or 8 (+dox) E9.5 Nanogtg embryos. ***P < 0.0005; Student’s t-test. Horizontal line represents mean values and error bars standard
deviation (SD).
E Representative FACS plots showing the distribution of cKit and CD41 populations in yolk sacs from untreated controls (dox) and Nanog expressing (+dox) E9.5
Nanogtg embryos.
F Quantification of different progenitor populations in yolk sacs from control (dox, black dots; n = 8) and Nanog expressing (+dox, red dots; n = 7) E9.5 embryos. Each
replicate contained a pool of 5 (dox) or 8 (+dox) E9.5 Nanogtg embryos. Horizontal line represents mean values and error bars SD.
G Differences in the expression levels of Nanog and selected hematopoietic genes in the CD71+ Ter119+ population of control (dox; n = 7) and Nanog expressing
(+dox; n = 4) E9.5 embryos. **P < 0.005, ***P < 0.0005; Student’s t-test. Horizontal line represents mean values and error bars SD.
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examined the expression of Kdr, a pan-mesodermal gene that acts
downstream of Brachyury; relative to the timing of Brachyury induc-
tion, dynamics of Kdr expression coincided in wild-type and
Nanog/ EBs. In contrast, erythroid gene activation occurred
earlier in Nanog/ EBs than in wild-type controls (Fig EV2B).
Thus, although mesoderm induction is delayed in Nanog/ EBs,
once it occurs the Nanog/ mesodermal cells show an elevated
potential for erythroid differentiation.
To further study the effect of loss of Nanog, we deleted a floxed
allele from a heterozygous ES cell line (Nanogflox/; Zhang et al,
2018) by transfecting Cre recombinase and differentiating sorted
GFP+ cells (that is activated upon Cre recombination) from ES to
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epiblast-like cells (Hayashi et al, 2011; Murakami et al, 2016). This
process recapitulates in culture the transition from pluripotent cells
of the blastocyst to primed cells of the epiblast (Buecker et al,
2014), a time window during development when Nanog is
expressed. Mutant cells (Nanogdel/) upregulate Brachyury follow-
ing the same dynamics as control heterozygote Nanogflox/ cells.
However, they show precocious activation of erythroid gene expres-
sion (Fig EV2C), in line with our previous observations.
Blockade of adult erythrocyte maturation by Nanog
Nanog has mostly been analyzed in early developmental stages and
in pluripotent stem cells. However, some reports have described its
expression and roles in adult tissues and cells (Tanaka et al, 2007;
Kohler et al, 2011; Piazzolla et al, 2014). In light of our findings
during embryonic hematopoiesis, we explored the effects of Nanog
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Figure 2. Wild-type ES cells rescue erythroid maturation in chimeric embryos.
A Experimental design for chimera generation, and contribution of GFP cells to chimeric embryo (right hand side panels).
B Freshly dissected dox-treated Nanogtg E10.5 embryos without (control) and with (chimera) contribution of wt-ESGFP cells (left, brightfield; right, GFP). Arrows mark
the presence of blood in chimeric embryos that is absent from controls. Scale bar, 500 lm.
C Representative FACS plots showing of red blood cell maturation as determined by CD71/Ter119 staining in single dox-treated E10.5 control (left) and chimeric
(right) embryos.
D–F Quantification of the CD71+ Ter119+ population in single dox-treated E10.5 embryos (D; control, n = 18; chimera, n = 10), untreated embryos (E; control, n = 7;
chimera, n = 12), and in GFP cells (not derived from wild-type ES cells) from dox-treated embryos (F; control, n = 18; chimera, n = 10). ***P < 0.0005; Student’s t-
test. Horizontal line represents mean values and error bars SD.
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Nanog expression was systemically induced in adult Nanogtg
mice by 5-day treatment with dox in drinking water, and the mice
were then sacrificed and bone marrow extracted (dox+; Fig 4A). As
controls, we used untreated mice of the same genotype (dox).
Analysis of erythrocyte maturation with CD71 and Ter119
(Socolovsky et al, 2001; Zhang et al, 2003) revealed an increase in
immature populations (basophilic and polychromatic erythroblasts;
S2 and S3, respectively) together with a decrease in the number of
more differentiated erythroblasts (orthochromatic erythroblasts, S4;
Fig 4B and C). This result suggested a block in the differentiation of
erythrocyte precursors, so we next quantified bone marrow progeni-
tors by flow cytometry using lineage cocktail, c-kit, Sca-1, CD34,
and CD16/32 (Fig 4D; Challen et al, 2009).
Induced Nanog expression triggered a decrease in absolute cell
numbers of hematopoietic stem cells (lineage-Sca1+cKit+; LSK) and
common myeloid progenitors (CMP), but no changes in granulo-
cyte–macrophage progenitors. Interestingly, this was accompanied
by a significant increase in megakaryocyte–erythroid progenitors
(MEP; Fig 4E). Analysis of the expression of key erythroid genes by
RT–qPCR in sorted MEPs revealed a significant reduction of Tal1 in
dox-treated mice (Fig 4F). Together, these results indicate that
Nanog can block the maturation of red blood cells during adult
hematopoiesis together with the downregulation of key erythroid
factors. This leads to defective differentiation of these populations
and therefore to an accumulation of their precursors.
We further characterized this phenotype by RNA-seq on the
MEPs from dox-treated and untreated adult Nanogtg mice. Genes
downregulated in MEPs from dox-treated animals were enriched in
functional terms related to bone marrow cell populations, and more
specifically MEPs (Fig EV3A). This confirms that Nanog is repress-
ing the transcriptional program for erythroid progenitors
(Fig EV3B). On the other hand, genes that are upregulated upon
Nanog induction are highly enriched in the mast cell program
(Fig EV3A and B; Dataset EV1). Most interestingly, deletion of Tal1
during adult hematopoiesis results in production of mast cells from
MEPs, while under normal conditions these cells derive from granu-
locyte–monocyte progenitors (Salmon et al, 2007). This is accompa-
nied by an upregulation of Gata2 (Salmon et al, 2007), a critical
specifier of mast cells (Ohmori et al, 2015), that we also see
increased upon Nanog expression in MEPs (Fig EV3B; Dataset EV1).
Furthermore, the expression of Cebpa, a factor that represses mast
cell lineage (Iwasaki et al, 2006), is downregulated in the Nanog-
expressing MEP population (Fig EV3B; Dataset EV1). However, we
believe that the positive regulation of the mast cell program is not a
physiological role of Nanog, because this cell type does not appear
during gastrulation (as erythroid progenitors do) but at later stages
in the yolk sac and the AGM (Gentek et al, 2018) where Nanog is
not expressed. Thus, we consider that upregulation of the mast cell
program is a secondary consequence of the downregulation of
erythroid lineage factors, such as Tal1, in Nanog expressing MEPs.
To extend these observations, we next carried out bone marrow
transplantation of Nanogtg mice to wild-type irradiated recipients
(Fig 4G). After 3 months of engraftment and recovery, more than
95% of peripheral blood cells were derived from donor mice (n = 7;
Fig 4H). We treated the mice for 4 months with dox to induce
Nanog expression only in hematopoietic cells, and found that at that
point the host cells had been partially able to recolonize the bone
marrow and contribute to peripheral blood cells (ranging from 20 to
80%; Fig 4H). We then purified bone marrow from the transplanted
mice and analyzed chimerism in different progenitor populations.
While LSK, CMPs of GMPs show variable degrees of contribution of
wild-type cells and Nanog expressing cells, MEPs are almost exclu-
sively derived from the host (Fig 4I). These results indicate that the
expression of Nanog in MEPs causes them to be outcompeted by
wild-type cells during bone marrow reconstitution, possibly due to
their decreased ability to differentiate and generate mature erythroid
cells.
A distal NANOG-binding element represses Tal1 expression in
the embryo
Nanog-mediated downregulation of erythroid specification genes in
both the embryo and the adult strongly suggests that some of these
genes are likely direct transcriptional targets of NANOG. If so, we
would expect to find mutually exclusive expression of Nanog and
these genes at the time of initial hematopoietic specification in the
gastrulating embryo. We therefore analyzed single-cell expression
data from E7.0 nascent mesoderm (Scialdone et al, 2016), when
Nanog is still expressed in the posterior-proximal region of the
embryo (Hart et al, 2004), and examined the number of cells
expressing both Nanog and markers of mesoderm (Brachyury, Cdx2)
and hematopoiesis (Tal1, Runx1, Gata1, Klf1; Fig 5A). For all of
these genes, we found the expected proportion of co-expressing cells
with Nanog with the exception of Tal1 (Fig 5A and B). We con-
firmed that Nanog can downregulate Tal1 at early stages by cultur-
ing Nanogtg embryos with or without dox from E6.5 to E6.75 ex
utero, which did not alter normal development (Fig 5C). Tal1 failed
to be upregulated in dox-treated embryos, whereas other
hematopoietic genes such as Klf1 were unaffected (Fig 5D). We
further confirmed that Nanog downregulates Tal1 by whole-mount
in situ hybridization of E7.5 embryos treated with dox in utero
(Fig 5E).
This evidence strongly suggests that Tal1 is a direct transcrip-
tional target of NANOG during early gastrulation at the onset of
◀ Figure 3. Nanog-knockout ES cells show increased potential to generate erythroid precursors.A Quantification of colony-forming units generated by wild-type (wt) and knockout (Nanog/) ES cells after culture of EBs for 5 (D5), 6 (D6), or 7 (D7) days and plating
disaggregated cells in different hemogenic-promoting conditions. Panels on the left show representative images of mouse hematopoietic colonies obtained after
12 days of culture in specific media. CFU-GEMM, progenitors giving rise to granulocytes, erythrocytes, monocytes, and megakaryocytes; BFU-E, burst forming units–
erythroid; Ery-P, colony-forming primitive erythroid; CFU-GM, granulocyte–monocyte precursors; CFU-M, monocyte precursors; CFU-G, granulocyte precursors. No
CFU-GEMM are detected at D5 and no BFU-E at D7. For both wt and knockout cells, n = 3 each with three technical replicates. *P < 0.05, **P < 0.005,
***P < 0.00005; Student’s t-test. Horizontal line represents mean values and error bars SD.
B RT–qPCR determination of the relative expression of Brachyury and selected hematopoietic genes in control (wt, right) and knockout (Nanog/, left) ES cells (n = 3)
during 10 days of EB differentiation in hematopoietic cytokine-enriched medium. Black arrowheads indicate the peak of Brachyury expression and white arrowheads
the time of maximum hematopoietic gene expression.
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hematopoietic determination. To investigate this possibility, we
analyzed published ChIP-seq data for NANOG binding in ES and
EpiLCs, which correspond to the E6.0 epiblast in the mouse embryo
(Murakami et al, 2016). This study describes a broad resetting of
NANOG-occupied genomic regions in the transition from ES cells to
EpiLCs, resembling the developmental progress from the naı̈ve inner
cell mass of the blastocyst to the primed epiblast at gastrulation
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of genomic loci, detecting binding at the Nanog locus itself in both
ES cells and EpiLCs (Fig EV4A) and in Cdx2 only in ES cells
(Fig EV4B). Neither cell type showed evidence of NANOG bound
regions surrounding Runx1 (Fig EV4C) or Klf1 (Fig EV4D). Interest-
ingly, EpiLCs, but not ES cells, showed NANOG binding 22 kilo-
bases upstream of Tal1, in an intron of the neighboring Stil gene
(Fig EV4E). We also detected NANOG binding downstream of Gata1
(Fig EV4F); however, these regions could be functionally related to
the neighboring Eras and Hdac6 genes, which are associated with
pluripotency and early stem cell differentiation (Takahashi et al,
2003; Chen et al, 2013).
Analysis of the Tal1/Stil NANOG bound region in EpiLCs
(Fig 5F) revealed bona fide consensus binding sites (Fig EV5A). To
investigate the function of this region, we deleted it by CRISPR/
Cas9-mediated genome editing (Ran et al, 2013) by microinjection
in one-cell stage embryos and examined the transcriptional conse-
quences in early development. Gene expression was analyzed by
RT–qPCR in individual edited E6.5 embryos. As controls, we used
embryos of the same batch showing no evidence of deletion of the
Tal1/Stil NANOG bound region (Fig EV5B). Tal1 expression was
significantly increased in targeted embryos, whereas other genes
such as Klf1, Gfi1b, or Runx1 were unaffected (Fig 5G). Deletion of
this genomic region did not alter Stil expression, despite the location
of the site within this gene (Fig 5G). These assays provide strong
evidence that this specific genomic region acts as a cis-regulatory
element in the Nanog-mediated repression of Tal1 in the early
mouse embryo.
In order to further confirm these observations and address the
effect of the deletion on Tal1 expression and its dependence on
Nanog, we analyzed the transition from ES to EpiLC in culture as
above. For this, we generated lines deleted for the distal Tal1
element by genome editing as previously described in vivo, but in
ES cells derived from the Nanogtg mouse (Figs 5H and EV5C). We
observe that non-treated Nanogtg ES cells (non-deleted control)
show a significant increase in Tal1 expression when they transit to
EpiLCs (Fig 5H), what would be the equivalent of the initial expres-
sion of Tal1 in the embryo. However, if dox is added to the medium,
this increase of Tal1 between ES and EpiLC is no longer significant.
Thus, in this experimental setting, increased expression of Nanog is
able to block at least partially the early induction of Tal1, in line
with our in vivo results. Nevertheless, when we repeat his experi-
ment but with two independent ES cell lines where the NANOG-
bound distal element (dTal1) has been deleted (Nanogtg;dTal1del#1
and Nanogtg;dTal1del#2), EpiLC become unresponsive to Nanog upon
dox treatment and still upregulate Tal1 as cells not treated with dox.
These results show that the distal element we have characterized is
necessary for correct initiation of Tal1 expression, and that it medi-
ates the response of Tal1 to Nanog.
Discussion
Red blood cell precursors are the first cell type to be specified from
nascent mesoderm during mouse gastrulation (Kinder et al, 1999;
Baron et al, 2012). While the genes and networks that determine
primitive hematopoietic cells are well understood (Isern et al, 2011;
Kingsley et al, 2013), much less is known about how precursors are
specified during the early stages of primitive streak formation
(Padron-Barthe et al, 2014). Here, we show that the pluripotency
factor NANOG regulates the transition from multipotent mesoder-
mal progenitors to red blood cell precursors in these early steps, at
least partially through the direct regulation of the lineage specifier
Tal1.
Despite the well-characterized role of pluripotency factors in
embryonic stem cells and the preimplantation embryo (Chambers &
Tomlinson, 2009), their function at later developmental stages has
received much less attention, even if they are expressed up to
gastrulation in mice (Yeom et al, 1996; Hart et al, 2004; Osorno
et al, 2012) and primates (Nakamura et al, 2016). Oct4 is involved
in proliferation of the primitive streak (DeVeale et al, 2013), in
correct trunk elongation of the trunk (Aires et al, 2016), and some
evidence points to it having a role in mesoderm and subsequent
hematopoietic specification (Kong et al, 2009). However, no clear
function is known for Nanog after implantation apart from the regu-
lation of germline development (Chambers et al, 2007). Single-cell
RNA-seq expression data from gastrulating embryos (Scialdone
et al, 2016) show that Nanog is expressed in a subset of mesodermal
precursors. This situation is reminiscent of the heterogeneities in
Nanog expression in the preimplantation embryo, which drives
lineage segregation of the epiblast and the primitive endoderm
◀ Figure 4. Induced Nanog expression blocks erythroid maturation in adult mice.A Experimental design for the treatment of adult Nanogtg mice.
B Representative FACS plots showing the distribution of different populations distinguished by CD71/Ter119 staining in whole bone marrow from untreated (dox) or
treated (+dox) adult mice. S0 (double negative cell), S1 (proerythroblast), S2 (basophilic erythroblast), S3 (polychromatic erythroblast), and S4 (orthochromatic
erythroblast) are different stages of blood maturation.
C Quantification of the S1–S4 erythroid populations (dox, n = 4; +dox, n = 5). *P < 0.05, **P < 0.005, ***P < 0.0005; Student’s t-test. Horizontal line represents mean
values and error bars SD.
D Representative FACS plots showing the distribution of CD16/32 and CD34 hematopoietic precursors sorted from the cKit+Sca1LIN bone marrow of untreated (dox)
or treated (+dox) adult Nanogtg mice.
E Quantification of precursor populations based on CD16/32 and CD34 sorting, as total number of cells per individual femur (dox, n = 5; +dox, n = 6). *P < 0.05,
**P < 0.005; Student’s t-test. Horizontal line represents mean values and error bars SD.
F RT–qPCR quantification of the relative expression of hematopoietic genes in megakaryocyte–erythroid progenitors (MEP; dox, n = 8; +dox, n = 5). *P < 0.05,
****P < 0.00005; Student’s t-test. Horizontal line represents mean values and error bars SD.
G Experimental design for the transplant of Nanogtg bone marrow to wild-type recipients and treatment of chimeric mice.
H Contribution of Nanogtg transplanted bone marrow cells to peripheral blood before (left) and after (right) dox treatment. Percentage of host-derived cells (CD45.1+)
are shown in black, and of donor derived cells (CD45.1/CD45.2 double +) in red. Individual mice are indicated on the x-axis (n = 7).
I Contribution of Nanogtg transplanted cells to LSK, CMP, GMP, and MEP populations purified from bone marrow. Percentage of host-derived cells (CD45.1+) are show
in black, and of donor derived cells (CD45.1/CD45.2 double +) in blue. Individual mice are indicated on the x-axis (n = 7).
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(Xenopoulos et al, 2015). Our results suggest that a similar situation
may occur during specification of the first mesodermal lineages.
Nanog expression in Brachyury-positive cells would maintain them
in a pan-mesodermal multipotent state, whereas its downregulation
would allow the expression of early hematopoietic lineage speci-
fiers, driving their differentiation to primitive red blood cells. This
process, however, occurs during a limited time window during the
initial phases of gastrulation, as Nanog is quickly downregulated by
E8.0–8.5 (Hart et al, 2004; Scialdone et al, 2016). By this stage,
mesodermal progenitors have ingressed through the primitive streak
and are no longer able to activate the early hematopoietic program,
a process that also involves restricted spatial signaling through the
Wnt and Bmp pathways (Cheng et al, 2008; Myers & Krieg, 2013;
Mimoto et al, 2015). Therefore, this Nanog-mediated switch would
act to control the rapid specification of blood precursors, the first
lineage determination event in gastrulation, and required to supply
the embryo with oxygen to support its subsequent exponential
growth.
We also show that Nanog directly represses the master
hematopoietic regulator Tal1 (Porcher et al, 2017) through an
upstream regulatory element located in an intron of the neighboring
Stil gene. Interestingly, this site is occupied by NANOG only during
the differentiation of ES cells to EpiLCs (Murakami et al, 2016). This
change in binding site usage during this transition again suggests
that Nanog has specific roles in the postimplantation pregastrulating
epiblast (the in vivo equivalent of EpiLCs; Hayashi et al, 2011) that
are distinct from those operating during the pluripotent state. Tal1
is certainly a prime candidate for mediating at least partially the
effects of Nanog on erythropoiesis, as we found that it is consis-
tently repressed at different embryonic stages and in adult erythroid
progenitors. However, surely other genes involved in early erythroid
development, such as Gata1, could be also direct Nanog targets
during this process. Further studies will unravel the full network
regulated by Nanog at these stages.
In the adult, Nanog expression leads to defective erythroid-cell
maturation, as also occurs in the embryo, and to an accumulation of
MEPs showing downregulation of Tal1. This can be explained by a
defect in the differentiation of these progenitors, and the phenotype
we observe is reminiscent of the adult-specific Tal1 knockout (Hall
et al, 2005). It is therefore tempting to speculate that the regulatory
circuit acting in the early embryo can be reenacted in the adult
solely by induction of Nanog.
Hematopoietic differentiation of Nanog/ ES cells (Chambers
et al, 2007) confirms the proposed role for Nanog in erythroid devel-
opment. Although Nanog/ cells show an initial delay in the acti-
vation of early pan-mesodermal markers such as Brachyury, once
this occurs, they show a faster and more coherent expression of
erythroid genes. Directed differentiation reveals that the lack of
Nanog promotes the red blood cell potential of these cells, which
show a marked increase in both primitive and more mature
erythroid colony formation. Our results show that Nanog acts as a
barrier to red blood cell development. Controlled downregulation of
Nanog during the initial phases of differentiation may present a
novel approach to boosting the generation of red blood cells from
pluripotent stem cells, a major clinical need (Kaufman, 2009).
Materials and Methods
Animal model
We obtained the Nanog/rtTA mouse line (R26-M2rtTA;Col1a1-tetO-
Nanog) (Piazzolla et al, 2014) from Manuel Serrano (CNIO, Madrid)
and Konrad Hochedlinger (Harvard Stem Cell Institute). This is a
double transgenic line that carries the M2-rtTA gene inserted at the
Rosa26 locus and a cassette containing Nanog cDNA under the
control of a doxycycline-responsive promoter (tetO) inserted down-
stream of the Col1a1 locus. Mice were genotyped by PCR of tail-tip
DNA as previously described (Hochedlinger et al 2005; Piazzolla
et al, 2014). Mice were housed and maintained in the animal facility
at the Centro Nacional de Investigaciones Cardiovasculares (Madrid,
Spain) in accordance with national and European Legislation. Proce-
dures were approved by the CNIC Animal Welfare Ethics Committee
and by the Area of Animal Protection of the Regional Government
of Madrid (ref. PROEX 196/14).
Double-homozygote transgenic males were mated with CD1
females, which were then treated with doxycycline (dox) to induce
the Nanog cassette by replacing normal drinking water with a 7.5%
sucrose solution containing dox (1 mg/ml), with replacement with
fresh solution after 2 days. For transgene induction in embryos to
◀ Figure 5. Direct transcriptional regulation of Tal1 expression by Nanog.A Expected and observed number of mesodermal (Flk1+) cells of the E7.0 mouse embryo expressing Nanog and selected mesodermal or hematopoietic gene expression,
based on single-cell RNA-seq data (Scialdone et al, 2016). Statistical significance was calculated with a hypergeometric test.
B PCA showing the distribution of Flk1+ E7.0 mesoderm cells expressing Nanog (green) or Tal1 (red). The single cell expressing both genes is shown in yellow and
indicated by an arrow.
C E6.5 Nanogtg embryos after 8 h ex utero culture in the presence (+dox) or absence (dox) of doxycycline. Scale bar, 100 lm.
D RT–qPCR quantification of the relative expression of Nanog, Tal1, and Klf1 in individual untreated embryos (dox) or treated embryos (+dox) (n = 5). **P < 0.005,
***P < 0.0005; Student’s t-test. Horizontal line represents mean values and error bars SD.
E Whole-mount in situ hybridization of Tal1 in E7.5 untreated (dox) or in utero treated (+dox) Nanogtg embryos. Scale bar, 100 lm.
F UCSC browser view of the Tal1/Stil1 region (mm9; chr4:114,705,753-114,756,741), indicating the presence of the NANOG binding peak, determined by ChIP-seq, in
EpiLCs (2 replicates are shown) but not in ES cells (Murakami et al, 2016); the binding peak was deleted by CRISPR/Cas9 genome editing (scissors).
G RT–qPCR determination of relative expression in wild-type and CRISPR-deleted embryos (n = 5) of Tal1 (wt, n = 19; deleted, n = 13), Klf1 (wt, n = 3; deleted, n = 6),
Gfi1b (wt, n = 10; deleted, n = 8), Runx1 (wt, n = 13; deleted, n = 5), and Stil (wt, n = 19; deleted, n = 13). **P < 0.005, Student’s t-test. Horizontal line represents
mean values and error bars SD.
H Experimental design for ES to EpiL cell differentiation of Nanogtg cells and two independent clones (Nanogtg;dTal1del#1 and Nanogtg;dTal1del#2) where the binding site
for NANOG distal to Tal1 has been deleted (left). On the right, relative expression of Tal1 determined by RT–qPCR for each ES cell line (ESC; n = 9 for all three lines)
and EpiL cells without (EpiLC; Nanogtg and Nanogtg;dTal1del#1, n = 8; Nanogtg;dTal1del#2, n = 6) or with dox treatment (EpiLC +dox; n = 9 for all three lines). The
genotype of the cell lines is indicated below. Values were normalized to Nanogtg ESC. *P < 0.05, **P < 0.01, ns = not significant; ANOVA with Fisher post-test.
Horizontal line represents mean values and error bars standard error of the mean (SEM).
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be harvested at E7.5, a single 100 ll intraperitoneal injection of
25 lg/ll doxycycline was administered to pregnant females at E5.5,
followed by dox administration in drinking water as above.
RT–qPCR assays
RNA was isolated from ESCs or sorted E9.5 cells using the RNeasy
Mini Kit (Qiagen) and then reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
RNA from individual E6.5-7.5 embryos or sorted bone marrow
populations was isolated using the Arcturus PicoPure RNA Isolation
Kit (Applied Biosystems) and reverse transcribed using the Quanti-
tect Kit (Qiagen).
cDNA was used for quantitative PCR (qPCR) with Power SYBR
Green (Applied Biosystems) in a 7900HT Fast Real-Time PCR
System (Applied Biosystems). Expression of each gene was normal-
ized to the expression of the housekeeping genes Actin and Ywhaz.
Primers used are listed in Dataset EV2.
Flow cytometry
E9.5 and E10.5 whole embryos or dissected yolk sacs were disaggre-
gated with 0.25% collagenase type I (Stemcell Technologies) at
37°C for 30 min, and the cells were washed with PBS containing
2% FBS (Gibco) and filtered through a 70-lm mesh. The single-cell
suspension was then incubated for 30 min at 4°C with the following
antibodies: anti-CD71-FITC (BD Biosciences), anti-Ter119-APC (BD
Biosciences), anti-cKit-PEcy7 (BD Biosciences), and anti-CD41-PE
(BD Biosciences). Samples were analyzed with the BD LSRFortessa
flow cytometer.
Bone marrow of adult mice was obtained from femurs and tibias
crushed in a mortar and filtered through a 70-lm mesh to obtain
single-cell suspensions. For hematopoietic cell maturation assays, a
small fraction of the bone marrow was separated and the rest was
depleted of red blood cells by lysis in FACSLysing solution (BD
Biosciences). Antibodies used for blood maturation assay were anti-
CD71-FITC (BD Biosciences) and anti-Ter119-APC (BD Biosciences).
Antibodies for BM precursor sorting were Biotinylated lineage cock-
tail (BD Biosciences), anti-CD34(RAM34)-FITC (BD Biosciences),
anti-cKit-PEcy7 (BD Biosciences), anti-CD16/32-BV605 (BD
Biosciences), and anti-Sca1-PerCP-Cy5.5 (BD Biosciences).
Cytospin cell preparation
For peripheral blood cytospin preparations, E9.5 embryos were
dissected in warm PBS with 2% FBS and EDTA 0.5 mM, puncturing
the yolk sac and the heart to let blood disperse into the media. All
the preparation was passed through a 70-lm filter, centrifuged for
5 min at 135 g, and resuspended in a final volume of 200 ll PBS.
Cells were collected on a glass slide on a Thermo ScientificCytospin
4 Cytocentrifuge for 10 min at 200 rpm and stained with May-
Grünwald-Giemsa. Slides were scanned on a NanoZoomer-2.0RS
C110730 scanner (Hamamatsu).
Cell culture
ESCs were maintained in serum-free conditions with Knock out
serum replacement (Thermo Fisher), LIF (produced in-house), and
2i (CHIR-99021, Selleckchem; and PD0325901, Axon). BT12 and
E14Tg2a ESCs were kindly provided by Ian Chambers and Austin
Smith (Chambers et al, 2007). ESC was differentiated toward hema-
topoiesis according to published protocols (Sroczynska et al, 2009;
Irion et al, 2010; Lesinski et al, 2012).
For embryoid body formation, 5000 ESCs were plated in
StemPro34 medium supplemented with nutrient supplement (Gibco)
and 2 mM l-glutamine (l-Gln), penicillin/streptomycin (Gibco),
50 lg/ml ascorbic acid, 200 lg/ml iron-saturated transferrin, 4 ng/
ml recombinant human BMP4, and 4 × 104 monothioglycerol.
After 2.5 days, to the cultures were added 5 ng/ml recombinant
human fibroblast growth factor 2 (rhFGF2; basic fibroblast growth
factor [bFGF]), 5 ng/ml recombinant human activin A, 5 ng/ml
recombinant human VEGF (rhVEGF), 20 ng/ml recombinant murine
thrombopoietin (TPO), and 100 ng/ml recombinant murine stem
cell factor (rmSCF). Cytokines were obtained from R&D Systems
Inc. or Peprotech. EBs were dissociated at day 6 by treatment with
0.05% trypsin-EDTA at 37°C for 2–5 min.
Dissociated EBs at day 5 and 6 were plated in Methocult SF
M3436 methylcellulose medium for quantification of primitive
erythroid progenitor cells (BFU-E). Dissociated EBs at days 5, 6, and
7 were plated in Methocult GF M3434 methylcellulose medium for
quantification of erythroid progenitor cells (CFU-E), granulocyte–
macrophage progenitor cells (CFU-GM, CFU-G, CFU-M), and multi-
potential granulocyte, erythroid, macrophage, and megakaryocyte
progenitor cells (CFU-GEMM). Cells were plated in triplicate on
ultra-low attachment surface plates (Corning) at 50,000 cells per
plate. Plates were incubated in high humidity chambers for 12 days
at 37°C and 5% CO2. Whole plates were counted. For qPCR, EBs
were directly lysed in extraction buffer and frozen at 80°C.
Nanog-floxed ES cells (Nanogflox/; Zhang et al, 2018) were trans-
fected with a Cre-expressing plasmid to induce recombination using
Lipofectamine 2000 (Invitrogen). After 48 h, GFP-positive cells
(Nanogdel/) and GFP-negative cells used as control (Nanogflox/)
were sorted using a FACS Aria Cell Sorter. Differentiation toward
EpiLCs was induced by plating 5 × 104 ES cells on a well of a 24-well
plate coated with human plasma fibronectin (10 lg/ml, Sigma) in
N2B27 medium supplemented with 20 ng/ml Activin A (Prepro-
tech),12 ng/ml bFGF (Preprotech), and 1% Knock out serum
replacement (Thermo Fisher) for 3 days.
Embryonic stem cells from Nanogtg mice were derived following
standard procedures (Nagy et al, 2003). Differentiation to EpiLCs
was performed in Nanogtg ES cells and in two different clones of
Nanogtg ES cells where the binding site upstream of Tal1 was
deleted (Nanogtg; dTal1del #1 and #2). Differentiation was induced by
plating 3 × 104 ES cells on a well of a 24-well plate and using the
same conditions above-mentioned. After 3 days of differentiation,
doxycycline (2 ng/ml) was added to the medium of the correspond-
ing wells to induce Nanog expression. One day later, EpiLCs with or
without doxycycline treatment were lysed for RNA isolation.
In situ hybridization and immunohistochemsitry
Embryos were collected in cold PBS, transferred to 4% PFA, and
fixed overnight at 4°C. After washing, embryos were dehydrated
through increasing concentrations of PBS-diluted methanol (25, 50,
75, and 2× 100%). In situ hybridization in whole-mount embryos
was performed as described (Ariza-McNaughton & Krumlauf, 2002;
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Acloque et al, 2008). Signal was developed with anti-digoxigenin-
AP (Roche) and BM-Purple (Roche). Images were acquired with a
Leica MZ-12 dissecting microscope. Probes for in situ were obtained
by PCR of cDNA with the primers listed in Dataset EV2.
For immunohistochemistry in whole mount, embryos were fixed
overnight at 4°C in 4% paraformaldehyde, followed by overnight
incubation at 4°C in primary antibody diluted 1:100 (rat monoclonal
anti-endomucin, Santa Cruz sc-65495; or rat monoclonal anti-CD31,
Santa Cruz sc-18916), washed and incubated overnight at 4°C with
1:500 Alexa Fluor 488 goat anti-rat (Termo Fisher Scientific, A-
11006) for Endomucin or HRP goat anti-rat (Termo Fisher Scientific,
31470) for CD31. For histology, embryos fixed as above were dehy-
drated through an ethanol series, cleared with xylene, embedded in
paraffin, sectioned at 5 lm, and stained with hematoxylin and
eosin.
RNA-seq
RNA was isolated from three replicates each of approximately
20,000 MEPs purified by sorting from adult untreated and dox-
treated Nanogtg mice. Sequencing was performed by the CNIC Geno-
mics Unit using the GAIIx sequencer. Adapters were removed with
Cutadapt v1.14 and sequences were mapped and quantified using
RSEM v1.2.20 to the transcriptome set from Mouse Genome Refer-
ence NCBIM37 and Ensembl Gene Build version 67. Differentially
expressed genes between the two groups were normalized and iden-
tified using the limma bioconductor package. Only P-values < 0.05
adjusted through Benjamini–Hochberg procedure were considered
as significant. Hierarchical clustering was performed on Z-scored
values of the selected genes to generate an overview of the expres-
sion profile. Functional enrichment analysis was conducted using
Enrichr (Kuleshov et al, 2016).
CRISPR/Cas9 genome editing
sgRNAs were designed using the CRISPR Design Tool from the
Zhang Lab at MIT (http://crispr.mit.edu/). Sequences of guide
RNAs are indicated in Fig EV5A. The two guide RNAs at 25 ng/ll
were incubated with the Cas9 protein (PNA bio) at 30 ng/ll and
microinjected into the pronuclei of (CBAxC57)F1 zygotes (1,490);
1,075 surviving embryos were transferred to CD1 pseudopregnant
females. 105 embryos were recovered at E6.5, and after discarding
delayed or malformed embryos, 72 were lysed in 100 ll extraction
buffer from the Arcturus PicoPure RNA Isolation Kit (Applied
Biosystems). Aliquots of 10 ll were used for DNA extraction for
PCR genotyping, and the remaining 90 ll was used for RNA extrac-
tion for RT–qPCR. Embryos for which we did not obtain a clear
genotype were discarded, as well as those for which RT–qPCR of
housekeeping genes did not reach a minimal threshold.
Embryonic stem cells from Nanogtg mice were electroporated with
Cas9 protein and sgRNAs as above. Individual clones were picked,
genotyped as above, karyotyped, and expanded for further use.
Statistical analysis
Statistical analysis was performed with the use of two-tailed
Student’s unpaired t-test analysis (when the statistical significance
of differences between two groups was assessed) or one-way
ANOVAs with subsequent Fisher post-test (when the statistical
significance of differences between more than two groups was
assessed). Prism software version 7.0 (Graphpad Inc.) was used.
For the analysis of the expected proportion of co-expressing cells
with Nanog, we used a hypergeometric test in R.
Data availability
Sequencing data have been deposited at GEO under accession
number GSE119467 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE119467).
Expanded View for this article is available online.
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